^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PLK1 (Polo Like Kinase 1)

    i
    Other names: PLK1, Polo Like Kinase 1, Serine/Threonine-Protein Kinase PLK1, Serine/Threonine-Protein Kinase 13, Polo-Like Kinase 1, STPK13, PLK-1, Cell Cycle Regulated Protein Kinase, Polo-Like Kinase (Drosophila), Polo (Drosophia)-Like Kinase
    2d
    Interaction of IRS2 with PLK1 protects cells from mitotic stress. (PubMed, Cell Death Dis)
    In contrast, cells expressing an IRS2 mutant that is not tyrosine phosphorylated display normal mitotic function. Together, our findings establish a mechanistic connection between IRS2 and mitotic regulation that is distinct from its function as a signaling adapter protein.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • PLK1 (Polo Like Kinase 1) • IRS2 (Insulin receptor substrate 2) • CDK1 (Cyclin-dependent kinase 1)
    10d
    PLK1 as A Potential Prognostic Marker of Gastric Cancer Through MEK-ERK Pathway on PDTX Models [Retraction]. (PubMed, Onco Targets Ther)
    [This retracts the article DOI: 10.2147/OTT.S169880.].
    Journal
    |
    PLK1 (Polo Like Kinase 1)
    15d
    Risk assessment of secondary primary malignancies: results from two large prospective European cohorts. (PubMed, NPJ Precis Oncol)
    Further, a single-cell sequencing analysis identified PLK1+ cancer stem cells as potential drivers of this causal relationship. Our findings provide important genetic evidence of the causal links between GC and specific SPMs, which may inform the optimization of precise follow-up strategies for GC survivors.
    Journal
    |
    PLK1 (Polo Like Kinase 1)
    17d
    Elucidating the potential carcinogenic molecular mechanisms of parabens in head and neck squamous cell carcinoma through network toxicology and molecular docking. (PubMed, PLoS One)
    Parabens may promote HNSCC progression by disrupting cell cycle regulation and immune responses via direct interactions with key hub genes. These findings provide a novel mechanistic basis for the carcinogenic potential of parabens in HNSCC and underscore the need for further experimental and epidemiological validation.
    Journal
    |
    CD8 (cluster of differentiation 8) • CDK4 (Cyclin-dependent kinase 4) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • CCNA1 (Cyclin A1) • CCNB1 (Cyclin B1) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    17d
    The Trifecta of Polo-like Kinases, Cancer, and the Immune System: Emerging Intersections and Therapeutic Insights. (PubMed, Mol Cancer Res)
    Understanding the intricate role of PLKs in cancer immunity is an emerging field with tremendous potential. This review offers a comprehensive overview of current knowledge connecting the members of the PLK family with cancer immunology and provides considerations for further research to uncover how PLK signaling can be strategically targeted to optimize cancer immunotherapy to enhance clinical responses.
    Journal
    |
    FASLG (Fas ligand) • PLK1 (Polo Like Kinase 1) • TGFB1 (Transforming Growth Factor Beta 1)
    17d
    Development of a three-dimensional collagen hydrogel model incorporating laurus nobilis extract-chitosan nanoparticles against ovarian cancer SKOV3 cells. (PubMed, Int J Artif Organs)
    Our developed model may be used for studying the effects of different anti-cancer drugs on ovarian cancer cells.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • PLK1 (Polo Like Kinase 1)
    21d
    Non-invasive host transcriptome and HPV oncogene expression map the molecular landscape of HPV-driven cervical lesions. (PubMed, PLoS One)
    By integrating transcriptomics profiling with current clinical testing, clinicians can distinguish transient infections from high-risks lesions likely to progress. This combined approach addresses the critical limitations of morphology and DNA-based methods, enabling more precise therapeutic interventions and reducing unnecessary overtreatment, and the risk of undertreatment or dismissal of high-risk cases.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • PLK1 (Polo Like Kinase 1) • CDK1 (Cyclin-dependent kinase 1) • DEFA1 (Defensin Alpha 1)
    21d
    Deubiquitinase USP38 Stabilizes PLK1 Expression to Boost DNA Damage Repair in Ovarian Cancer. (PubMed, Kaohsiung J Med Sci)
    Mechanically, silencing USP38 decreased the expression level of PLK1 protein, repressing DDR in cancer cells. Deubiquitinase USP38 binds to PLK1 to stabilize PLK1 expression, facilitating DDR in OC cells and enhancing cancer cell proliferation, thereby reducing the apoptosis rate of cancer cells.
    Journal
    |
    PLK1 (Polo Like Kinase 1)
    25d
    Multi-omics analysis identifies CCNB1 as a cell cycle factor driving glioblastoma progression and its inhibition by resveratrol. (PubMed, PLoS One)
    Collectively, these data suggest that CCNB1 is highly expressed in GBM and may promote GBM progression. Inhibition of CCNB1 may represent a potential therapeutic strategy for GBM.
    Journal
    |
    PLK1 (Polo Like Kinase 1) • CCNB1 (Cyclin B1)
    28d
    Targeting Prolyl 3-hydroxylase 1 inhibits pancreatic cancer progression and macrophage immunity. (PubMed, Nat Commun)
    In addition, pharmacological inhibition of Polo-like kinase 1 strongly increases the therapeutic efficacy of chemotherapeutic response against pancreatic ductal adenocarcinoma, alleviating tumor burden in mice. Our findings suggest a promising therapeutic strategy for treating pancreatic ductal adenocarcinoma.
    Journal
    |
    PLK1 (Polo Like Kinase 1)
    1m
    Identification of an Anoikis-Related Gene Signature to Predict the Prognosis in Patients With Oral Squamous Cell Carcinoma. (PubMed, Int Dent J)
    We have developed a novel 5-gene signature related to ARG, which may serve as a predictor for OS in patients with OSCC. Our findings may open a new possibility of providing personalised treatment for OSCC patients.
    Journal • Gene Signature
    |
    PLK1 (Polo Like Kinase 1) • GPX4 (Glutathione Peroxidase 4) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • PLAU (Plasminogen Activator)